Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

“In contrast, branded specialty products represent more than 50% of our clients’ total drug spend and are entirely ignored by the FTC.” Express Scripts, meanwhile, declared in a statement th ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

the FTC released another interim staff report showing how the industry’s top PBMs reaped billions from specialty drug markups. The agency sued the PBMs in 2024. Cigna acquired Express Scripts in ...

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...

"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...